Dimethyl fumarate (Skilarence®) for the treatment of plaque psoriasis in adults
The Minister of Health, Welfare and Sport (WVS) asked Zorginstituut Nederland (National Health Care Institute) to carry out an assessment of whether dimethyl fumarate (Skilarence®) is interchangeable with a medicinal product that is already included in the Medicine Reimbursement System (GVS). The Zorginstituut has completed its assessment.
Advice
Based on the current criteria for interchangeability, dimethyl fumarate (Skilarence®) is interchangeable with another medicinal product in the GVS that has the same active substance, namely Tecfidera®.
Thus, in principle, Skilarence® is eligible for inclusion on List 1A in a new cluster with Tecfidera®. This is in keeping with the Ministry's policy to minimise off-label use and to give preference to registered products. However, its inclusion in the GVS will be accompanied by additional costs amounting to approximately €7 million in comparison with the existing pharmacy preparations.
This report is a summary of recommendations by Zorginstituut Nederland. The original text of this excerpt is in Dutch.